אומר-יג-אם % 5 - % Omr-Igg-am 5

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

J06BA
Immunoglobulins, normal human

××¨××× ×¤×¢×× (ATC5)

Immunoglobulins, normal human, for intravascular administration 50 MG/ML MG/ML âJ06BA02

×¦××¨×ª ××ª×

×ª××-××¨××× - I.V

×¦××¨×ª ××× ××

×ª×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Replacement therapy * PRIMARY immunodeficiency (patients with PRIMARY defective antibody synthesis such as agammaglobulinemia OR hypogammaglobulinemia) * Myeloma OR chronic Lymphocytic Leukemia (CLL) with severe secondary hypogammaglobulinemia AND recurrent infections. * Children with congenital AIDS AND recurrent infections - Immunomodulation * Idiopathic Thrombocytopenic Purpura (ITP) * Guillain Barre Syndrome * Kawasaki Disease - Allogenic Bone Marrow Transplantation

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

01/01/1995

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××©××××© ×××ª× ××××× ×× ××©×¤×× ×××

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
×××¤×× ××××× ×××§××× ××¡×× CLL ××¡××××× ××××¤×××××××××××× ××× ××©× ××ª ××××¨× ×××××××× ××××¨××.	01/01/1995
CIDP â Chronic inflammatory demyelineating polyneuropathy	01/01/1995
××¡×¨ ×××¡×× × ×¡×¤×¦××¤×, ×× ××¢× ×× ×××¤×× ×××¦××ª, ××¤×××××¡ A ×××¨××××ª	01/01/1995
××¡×¨ ×××¡×× × ×¨××©×× × (××××× ×¢× ×¤×××¢× ×¨××©×× ××ª ××××¦××¨ × ×××× ×× ×××× ××××××××××× ××× ×× ×××¤××××××××××× ×××, ITP (Idiopathic thrombocytopenic purpura))	01/01/1995

×©××××© ××¡×

Primary immunodeficiency (patients with primary defective antibody synthesis such as agammaglobulinemia or hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP)

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××§×¨×× ××××:

×. ××¡×¨ ×××¡×× × ×¨××©×× × (××××× ×¢× ×¤×××¢× ×¨××©×× ××ª ××××¦××¨ × ×××× ×× ×××× ××××××××××× ××× ×× ×××¤×××××××××××× ×××, ITP (Idiopathic thrombocytopenic purpura));

×. ××¡×¨ ×××¡×× × ×¡×¤×¦××¤×, ×× ××¢× ×× ×××¤×× ×××¦××ª, ××¤×××××¡ A ×××¨××××ª;

×. CIDP â Chronic inflammatory demyelineating polyneuropathy;

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 31.05.2025

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××××¨-××-××Â % 5 ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	OMRIX BIOPHARMACEUTICALS LTD. PLASMA FRACTIONATION INSTITUTE (PFI), ISRAEL
×©× ××¢× ××¨××©××	OMRIX BIOPHARMACEUTICALS
×¨××©×××	×ª××¨×× ×××©×: 12/2002. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	09/01/2026

×ª××× ×ª ××¨×××

×ª××× ×ª ××¨×××

השינוי האחרון נעשה בֹ־9 בינואר 2026 ב־08:20

אומר-יג-אם % 5 - % Omr-Igg-am 5

ויקיתרופות